CD Biopharma Receives FDA Clearance for Phase I Clinical Trial of CD-001
CD-001, the company's clinical candidate, is built on its proprietary Bispecific Fusion Protein (BsFP) platform.
CD Biopharma | 20/09/2024 | By Aishwarya | 165
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy